Focus on immune-related adverse events (irAEs) in immunotherapy of hepatobiliary malignancies

Lei Zhang, Haitao Zhao


There has been a chronic lack of effective treatment for hepatobiliary malignancies, and overall survival of comprehensive therapy, including targeted chemotherapy, is still low (1,2). A series of immune checkpoint blockade drugs have offered new choices for patients with advanced hepatobiliary malignancies.

Article Options

Download Citation